MARKET

IMV

IMV

IMV Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.750
0.000
0.00%
Opening 10:14 09/23 EDT
OPEN
1.740
PREV CLOSE
1.750
HIGH
1.750
LOW
1.735
VOLUME
11.55K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.310
MARKET CAP
143.75M
P/E (TTM)
-4.1022
1D
5D
1M
3M
1Y
5Y
INO, SFIX and TECK among pre market gainers
Marin Software (NASDAQ:MRIN) +80%. Aethlon Medical (NASDAQ:AEMD) +34%. Onconova Therapeutics (NASDAQ:ONTX) +24% announces encouraging clinical data supporting the anti-cancer activity of rigosertib-nivolumab Combination in advanced KRAS+ non-small cell lun...
Seekingalpha · 1d ago
Cantor Fitzgerald Initiates Coverage On IMV with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Brandon Folkes initiates coverage on IMV (NASDAQ:IMV) with a Overweight rating and announces Price Target of $4.
Benzinga · 1d ago
--Cantor Fitzgerald Starts IMV at Overweight With $4 Price Target
MT Newswires · 1d ago
IMV Inc. to Present at Three Investor Conferences in September
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., September 01, 2021--IMV Inc. to Present at Three Investor Conferences in September
Business Wire · 09/01 11:05
3 Small Cap Stocks Not Worth the Risk
StockNews.com · 08/31 16:09
First City Capital Management, Inc. Buys Vanguard Short-Term Government Bond ETF, WisdomTree ...
GuruFocus News · 08/16 20:38
IMV Q2 EPS $(0.11) Down From $(0.08) YoY, Sales $42.00K Up From $40.00K YoY
IMV (NASDAQ:IMV) reported quarterly losses of $(0.11) per share. This is a 37.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $42.00 thousand in sales this
Benzinga · 08/11 11:10
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., August 11, 2021--IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
Business Wire · 08/11 11:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMV. Analyze the recent business situations of IMV Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMV stock price target is 9.75 with a high estimate of 14.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 9.32M
% Owned: 11.35%
Shares Outstanding: 82.14M
TypeInstitutionsShares
Increased
6
233.73K
New
7
174.63K
Decreased
10
273.56K
Sold Out
4
216.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About IMV
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMV stock methods without spending real money on the virtual paper trading platform.